BioNTech SE (BNTX)

Market Cap	26.83B
Revenue (ttm)	3.39B
Net Income (ttm)	-520.75M
Shares Out	239.74M
EPS (ttm)	-2.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	446,138
Open	113.56
Previous Close	112.76
Day's Range	111.93 - 114.67
52-Week Range	76.53 - 131.49
Beta	0.19
Analysts	Strong Buy
Price Target	145.28 (+29.8%)
Earnings Date	Nov 4, 2024

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2019
• Employees: 6,133
• Stock Exchange: NASDAQ
• Ticker Symbol: BNTX
• Website: https://www.biontech.de

Financial Performance

In 2023, BioNTech SE's revenue was 3.82 billion, a decrease of -77.94% compared to the previous year's 17.31 billion. Earnings were 930.30 million, a decrease of -90.14%.

Financial numbers in EUR

Analyst Forecast

According to 16 analysts, the average rating for BNTX stock is "Strong Buy." The 12-month stock price forecast is $145.28, which is an increase of 29.80% from the latest price.

Price Target

$145.28

(29.80% upside)

Analyst Consensus: Strong Buy